trans-2-<4-Isopropyl-styryl>-pyridin | 726-36-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: trans-2-<4-Isopropyl-styryl>-pyridin
• 英文别名: 2-(4-isopropyl-styryl)-pyridine；2-(4-Isopropyl-styryl)-pyridin；2-[(E)-2-(4-propan-2-ylphenyl)ethenyl]pyridine
• CAS: 726-36-3
• 化学式: C₁₆H₁₇N
• 分子量: 223.318
• InChiKey: OZJUMMCNVDUDKR-DHZHZOJOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  二硫化碳 、 trans-2-<4-Isopropyl-styryl>-pyridin 、 溴 生成 alkaline earth salt of/the/ methylsulfuric acid
  参考文献：
  名称：

  Backe, Chemische Berichte, 1901, vol. 34, p. 1895

  摘要：

  DOI：
• 作为产物：
  描述：

  碳酸甲丙酯 、 4-异丙基苯甲醛 生成 trans-2-<4-Isopropyl-styryl>-pyridin
  参考文献：
  名称：

  Backe, Chemische Berichte, 1901, vol. 34, p. 1895

  摘要：

  DOI：

文献信息

• Analogs of fexaramine and methods of making and using
  申请人：Salk Institute for Biological Studies

  公开号：US10301268B2

  公开（公告）日：2019-05-28

  Novel compounds having a formula embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.

  具有以下式子的新型化合物 本文公开了具有式的新型化合物、其制造方法的实施方案以及包含它们的组合物。还公开了一种治疗或预防受试者代谢紊乱的方法的实施方案，包括向受试者施用（例如通过胃肠道）治疗有效量的一种或多种已公开化合物，从而激活肠道中的FXR受体，治疗或预防受试者的代谢紊乱。此外，还公开了一种治疗或预防受试者肠道区域炎症的方法的实施方案，该方法包括向受试者施用（例如，经由胃肠道）治疗有效量的一种或多种所公开化合物，从而激活肠道中的FXR受体，进而治疗或预防受试者肠道区域的炎症。
• ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING
  申请人：Salk Institute for Biological Studies

  公开号：US20170066724A1

  公开（公告）日：2017-03-09

  Novel compounds having a formula embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.
• INTESTINAL FXR AGONISM ENHANCES GLP-1 SIGNALING TO RESTORE PANCREATIC BETA CELL FUNCTIONS
  申请人：Salk Institute for Biological Studies

  公开号：US20180000768A1

  公开（公告）日：2018-01-04

  Disclosed are embodiments of a method of treating or preventing latent autoimmune diabetes of adults (LADA) in a subject. Such embodiments include administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or farnesoid X receptor (FXR) agonist compounds, thereby activating FXR receptors in the intestines, and treating or preventing latent autoimmune diabetes of adults (LADA) in the subject.